PT  - JOURNAL ARTICLE
AU  - Marina Petrovic
AU  - Ivan Cekerevac
AU  - Zorica Lazic
AU  - Vojislav Cupurdija
AU  - Dejan Petrovic
AU  - Rada Vucic
AU  - Gordana Kostic
TI  - Evaluation of IL-33 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC)
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P2705
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P2705.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P2705.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - AIM: To study the relationship between the interleukin-33 (IL-33) level in serum and broncheoalveolar lavage fluid (BALF) and non-small cell lung cancer (NSCLC).METHODS:The concentration of IL-33 in serum or BALF of 96 NSCLC patients, 47 patients of pulmonary inflammatory diseases (PID) and 32 normal controls were measured by ELISA.RESULTS:The concentration of IL-33 in BALF of NSCLC patients was significantly higher than that of PID patients and normal controls (P<0.01). The concentration of IL-33 in sera of NSCLC patients was higher than that of normal controls (P<0.01) but not statistically different from that of PID patients. In patients with NSCLC, the concentration of IL-33 in BALF was slightly higher than that of serum IL-33, but this difference was not statistically significant (P>0.05). Serum IL-33 level was higher in NSCLC of advanced stages (stage IIIa, IIIb and IV), as compared with that in NSCLC patients of early stages (stage Ia-IIb). BALF IL-33 level of NSCLC patients at different stages was not different. IL-33 (level in serum but not in BALF) of PID patients correlated with the serum concentration of C reactive protein (r=0.72).CONCLUSION: IL-33 in BALF might be used as a marker for NSCLC. Serum IL-33 level might be an indicator for the stage of NSCLC. The serum IL-33 can also reflect the severity of acute lung inflammatory response.Key words: non-small cell lung cancer, interleukin-33, bronchoalveolar lavage.